NCT01427504View on ClinicalTrials.gov

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Hepatitis CHIV
Interventions
DRUG

boceprevir; etravirine

boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT01427504 - Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers | Biotech Hunter | Biotech Hunter